[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hai-Qiang Mai,MD,PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100598477","phase-3-shrinking-the-anterior-border-of-ctv2-for-nasopharyngeal-carcinoma-to-reduce-the-radiation-of-nasal-cavity-100598477",false,"NCT07072000","Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity","Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity : an Open-label, Non-inferiority, Multicenter, Randomized Phase III Trial","Inclusion Criteria:\n\n1. Newly diagnosed, histologically confirmed non-keratinizing carcinoma (WHO classification).\n2. Stage I-III disease (AJCC 9th edition).\n3. Tumor extends to nasal cavity (including nasal septum).\n4. No distant metastasis (M0).\n5. Age 18-70 years.\n6. Male or non-pregnant female.\n7. Scheduled for radiotherapy.\n8. ECOG performance status 0-1 .\n9. Adequate bone marrow function: white blood cells \\>4×10⁹\u002FL, hemoglobin \\>90 g\u002FL, platelets \\>100×10⁹\u002FL.\n10. Normal hepatic\u002Frenal function: total bilirubin ≤1.5×ULN, AST\u002FALT ≤2.5×ULN, alkaline phosphatase ≤2.5×ULN, creatinine clearance ≥60 mL\u002Fmin.\n11. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Keratinizing squamous cell carcinoma (WHO Type I) or basaloid squamous cell carcinoma.\n2. Age \\\u003C18 or \\>70 years.\n3. Recurrent disease or distant metastasis.\n4. No tumor extension into the nasal cavity (including the nasal septum).\n5. Prior malignancy (except adequately treated basal\u002Fsquamous cell skin cancer or cervical carcinoma in situ).\n6. Pregnancy\u002Flactation (premenopausal women require pregnancy test; effective contraception mandated).\n7. Prior radiotherapy (except non-melanoma skin cancer with lesions outside current portals).\n8. Preoperative chemotherapy or surgical resection of primary\u002Fneck lesions (excluding diagnostic procedures).\n9. Severe coexisting illness.","ALL","18 Years","70 Years",{"count":20,"type":21},550,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into the posterior nasal aperture.",[27],"Nasopharyngeal Cancinoma (NPC)",[29,30],"nasopharyngeal carcinoma","radiotherapy","NOT_YET_RECRUITING","2025-07-16",{"date":34,"type":35},"2025-07-18","ACTUAL",{"date":37,"type":21},"2025-08-01",{"date":39,"type":21},"2032-07-31",{"name":41,"class":42},"Hai-Qiang Mai,MD,PhD","OTHER",5,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100586232","phase-3-reduced-dose-radiotherapy-vs-standard-dose-radiotherapy-for-early-stage-nasopharyngeal-carcinoma-100586232","NCT06912698","Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma","A Phase III Randomized Controlled Non-Inferiority Clinical Trial Comparing Reduced-Dose Versus Standard-Dose Radiotherapy Based on Treatment Response in Early-Stage Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age 18-70, regardless of sex.\n2. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, type of WHO II or III, clinical stage I (according to the 9th American Joint Committee on Cancer\\[AJCC\\] edition).\n3. Patients with CR according to RECIST and EBV DNA undetectable after received 50.88Gy radiation.\n4. ECOG (Eastern Cooperative Oncology Group) score: 0-1.\n5. Women in their reproductive years should ensure that they use contraception during the study period.\n6. Hemoglobin (HGB) ≥90 g\u002FL, white blood cell (WBC) ≥4×109 \u002FL, platelet (PLT) ≥100×109 \u002FL.\n7. Liver function: Alanine transaminase(ALT), Aspartate aminotransferase(AST)\\\u003C 1.5 times the upper limit of normal value (ULN), total bilirubin \\\u003C1.5×ULN.\n8. Renal function: serum creatinine \\\u003C1.5×ULN or creatinine clearance rate≥60mL\u002Fmin.\n9. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule.\n\nExclusion Criteria:\n\n1. Histologically confirmed keratinizing squamous cell carcinoma (WHO I).\n2. Patients with PR\u002FSD\u002FPD according to RECIST and\u002For EBV DNA detectable after received 50.88Gy radiation.\n3. Receiving radiotherapy or chemotherapy or targeted therapy previously.\n4. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.\n5. Suffered from other malignant tumors (except the cure of basal cell carcinoma or uterine cervical carcinoma in situ) previously.\n6. Patients with significantly lower heart, liver, lung, kidney and bone marrow function.\n7. Severe, uncontrolled medical conditions and infections.\n8. At the same time using other test drugs or in other clinical trials.\n9. Refusal or inability to sign informed consent to participate in the trial.\n10. Other treatment contraindications.\n11. Emotional disturbance or mental illness, no civil capacity or limited capacity for civil conduct.",{"count":52,"type":21},342,[24],"This study investigates whether administering reduced dose is non-inferior to standard dose radiotherapy in terms of 3-year locoregional relapse-free survival (LRRFS) rate for stage I nasopharyngeal carcinoma patients who are sensitive to radiotherapy.",[27],[30,57],"dose","RECRUITING","2025-04-16",{"date":61,"type":35},"2025-04-22",{"date":63,"type":21},"2025-05-22",{"date":65,"type":21},"2033-03-19",{"name":41,"class":42},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":16,"minAge":4,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100334689","the-children-and-adolescents-nasopharyngeal-carcinoma-survivor-study-100334689","NCT03637634","The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study","CANPCSS","Inclusion Criteria:\n\n* Patients or their siblings must be informed of the investigational nature of this study and give written informed consent.\n\n  * Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma (including differentiated type and undifferentiated type, WHO II or III) before age 21 years at one of participating centers.\n\nExclusion Criteria:\n\n* Already involved in other blind clinical trial.\n* The information of tumour response evaluation and survival data cannot be obtained.",true,"21 Years",{"count":78,"type":21},1000,"OBSERVATIONAL","The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study will investigate the long-term effects of nasopharyngeal carcinoma (NPC) and its associated therapies. A prospective and retrospective cohort study will be conducted through a multi-institutional collaboration. This project will study children and adolescents exposed to specific therapeutic modalities, including radiation, chemotherapy, and\u002For surgery, who are at increased risk of late-occurring adverse health outcomes. A group of sibling controls will be identified and data collected for comparison purposes.",[82],"NPC Patients",[84],"children and adolescents","2018-08-26",{"date":87,"type":35},"2018-08-28",{"date":89,"type":21},"2018-09-01",{"date":91,"type":21},"2035-12-31",{"name":41,"class":42},""]